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Retrospective database studies of PAH using US payer claims data have limitations 
due to lack of specific ICD-9 codes for PAH and ability to identify patient severity. 
Previous studies used an algorithm which includes patients with non-specific PH 
codes, along with a claim for an advanced PAH drug therapy. This study attempts 
to validate the algorithm and identify patient disease severity through linkage to 
data abstracted from medical charts. Objectives: To evaluate validity of a retro-
spective review of payer database along with chart abstraction for confirmation of 
PAH diagnosis and identification of World Health Organization Functional Class 
(FC). MethOds: Medicare patients who received an (1) endothelin-receptor antago-
nist, phosphodiesterase type 5 inhibitor, or prostacyclin AND (2) had a diagnosis of 
pulmonary hypertension, other chronic pulmonary hypertension or chronic pulmo-
nary heart disease OR (3) medical claim indicating right heart catheterization (RHC) 
were identified from pharmacy and medical claims data. A random sub-sample of 
110 patients was chosen and the providers contacted to provide medical charts. 
Charts were reviewed to abstract data indicating PAH diagnosis, FC, and/or symp-
toms, diagnostic tests, and treatments to enable classification. Results: Of 110 
charts requested, 41 were received and abstracted. Twenty-one charts (51%) came 
from a specialist. All 41 charts documented a confirmed diagnosis of PAH. Of those, 
18 (44%) explicitly identified PAH class. Physical symptoms were reported, with dysp-
nea (66%) being most frequent, while walk test results, documentation of RHC and 
pulmonary diagnostic tests were reported in less than 20% of cases. cOnclusiOns: 
The identification algorithm successfully identified diagnosed, confirmed cases 
of PAH. Refinements to provider selection algorithm could result in an increase in 
provider response rate, charts with documented FC and overall chart data quality.
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Objectives: We conducted a systematic review to appraise the methodological 
quality of controlled clinical trials evaluating the efficacy and safety of Chinese 
herbal medicine (CHM) patients with rheumatoid arthritis (RA). MethOds: We 
searched electronic databases (Medline, EMBASE, The Cochrane Library, and Web 
of Science) from inception until May 2014. Study selection was performed by 2 
independent reviewers. The methodological quality of the trials was assessed using 
the Cochrane risk of bias tool for randomized trials and Newcastle Ottawa Scale 
for controlled non-randomized studies. Results: 54 studies were included (51 
randomized trials; 3 non-randomized studies) evaluating 7,792 patients. Only one 
study was conducted in the US, the remaining in China. There were 3,446 patients 
receiving CHM. In the control groups 2,283 patients received a disease modifying 
anti-rheumatic drug (DMARD), 182 non-steroidal anti-inflammatory drugs (NSAIDs), 
and 164 inert placebo. For the randomized studies, when evaluating selection bias 
54% of the studies were judged to have an adequate random sequence generation, 
but 77% had inadequate allocation concealment. 79% had a high risk of performance 
bias (not blinding participants and/or personnel) and detection bias was unclear 
in 56% of the studies; 62% of the studies reported how missing data was handled, 
therefore attrition bias was judged to be low. In 87% no disclosure of interest or 
source of founding was reported. For non-randomized studies, all the studies were 
representative of RA patients, had an adequate ascertainment of intervention with 
comparable groups, but only one demonstrated that the outcome of interest was not 
present at start of study or provided the rate of lost to follow-up. cOnclusiOns: 
Studies evaluating CHM often fail to meet expected methodological criteria, and 
high quality evidence is lacking. Future studies of CHM should be methodologically 
robust and adhere to reporting guidelines such as the CONSORT statement for TCM.
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Objectives: Health economists are being encouraged to use routine datasets for 
resource-use measurement and costing purposes in economic evaluations alongside 
clinical trials to reduce research burden. The Hospital Episode Statistics (HES) data-
set, which records all NHS hospital-based activity in England, is one such dataset. 
However, its validity for research purposes has not been established. This study 
aims to assess the validity of the HES outpatient dataset. MethOds: Men who 
died of, or with, prostate cancer were selected from a prostate-cancer screening 
trial (CAP, Cluster randomised triAl of testing for Prostate cancer). Details of visits 
that took place after 1/4/2003 to hospital outpatient departments for conditions 
related to prostate cancer were extracted from medical records (MR). Data from the 
HES outpatient dataset were obtained for the same men. Appointments for visits 
extracted from MR were sought in the HES dataset. The matching procedure was 
repeated for periods before and after 1/4/2008 (when the dataset was accredited as 
a national statistic). Results: 4922 outpatient appointments were extracted from 
MR for 370 men between 2003 and 2012. 4086 appointments recorded in MR were 
identified in the HES dataset (83.0%; 95%CI 81.9–84.1). Allowing a +/-2 day tolerance 
for the appointment date resulted in a slight improvement to 4171 (84.7%; 95%CI 
83.7–85.7) matches (p= 0.5). For appointments occurring when the dataset was con-
sidered experimental (prior to 1/4/2008), 2194/2754 (79.7%; 95%CI 78.1–81.2) matches 
were observed, while 1892/2168 (87.3%; 95%CI 85.8–88.6) appointments occurring 
after 1/4/2008 were identified (p= 0.03). cOnclusiOns: The HES outpatient data-
Objectives: This research will present the Bayesian decision analytic framework 
for late phase study simulation and calculation of chance of study success applied 
to optimal target population and study design. A real-world example in mother-
to-child transmission of HIV conducted in Thailand will be used to illustrate the 
concepts throughout. MethOds: Predictive models describing virtual cohorts over 
time under various care strategies can be informed via Bayesian inference using all 
relevant data available on associations between population characteristics, relative 
drug efficacy, drug uses and design parameters. In the proposed example, historical 
transmission data from 3,876 Thai women were modeled via mixed-effect logistic 
regression adjusted for viral load, gestational age, CD4 count at delivery and infant 
treatment duration. Viral load was described as an exponential function of prophy-
laxis duration. Monte Carlo simulations were used to predict intrapartum transmission 
rates with and without single dose nevirapine (sdNVP) added to the standard of care 
(antenatal prophylaxis), and predict chance of success of a naturalistic Phase IIIb 
study in Thailand under various assumptions on target population and adaptive study 
design. Results: In women with short prophylaxis durations (< 8-weeks) estimate of 
intrapartum transmission rate was 2.6% (95%-Credibility Interval= 0.5%-9.2%) with the 
standard of care and 0.8% (95%-CI= 0.1%-2.9%) with sdNVP added to standard care, 
corresponding to a risk ratio of RR= 3.9 (95%-PI= 2.1-9.7). Study simulations showed 
that a single-arm study with stopping rules at N= 58, 118, 275, and 410 has 78% (resp. 
68%) probability of evidencing RR> 1.3 (resp. RR> 2). cOnclusiOns: When the associa-
tion between outcomes, design parameters and the main effectiveness drivers can 
be informed by historical data, Bayesian predictive models can be powerful decision 
support tools for optimal target population and late-phase or pragmatic study design.
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Objectives: The aim of the study was to assess the delayed-time effect on survival 
of the immunotherapy with a cancer vaccine by comparing the conventional logrank 
test vs a weighted logrank in presence of non-proportional hazards. MethOds: 
Data from a multicenter, open-label and randomized phase III clinical trial with 
an EGF-based cancer vaccine in advanced NSCLC. The diagnosis of the delayed-
time effect was done and the time-delay was estimated. The non-proportional 
hazards were also confirmed and tested delayed effect on survival of the treat-
ment. Weighted logrank tests was applied and the results were compared with 
those obtained using the conventional logrank test. The R software was used in 
the analysis. Results: The time-delay was estimated in 28 months and a signifi-
cant effect after this time was verified. The proportional hazard assumption was 
not satisfied. The median survival for the vaccinated arm was 10.37 months vs. 
8.93 months for non-vaccinated arm. The difference was statistically significant by 
weighted logrank (p= 0.04) and the conventional logrank test does not detect this dif-
ference. cOnclusiOns: Weighted logrank is substantially more efficient than the 
conventional logrank statistic in those situations in which non-proportional hazards 
are foreseen. This analysis is recommended for immunotherapies where the appear-
ance of a late biological effect is displayed several months after randomization.
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Objectives: The degree to which predefined risk factor (RF) changes alter long-term 
clinical and cost outcomes in the IMS-CORE-Diabetes-Model (CDM) was reported 
in earlier publications. Since this time the CDM has undergone a series of updates 
including the inclusion of recently published UKPDS-82 risk equations (UK-82-RE). The 
objective of this study was to project the lifetime benefits and total lifetime costs (TLC) 
associated with a range of selected RF changes opposing results from CDM projections 
utilizing UKPDS-68 risk equations (UK-68-RE) vs. UK-82-RE. MethOds: The CDM was 
applied to project the lifetime benefits (life years (LYs), quality adjusted life years 
(QALYs)) and TLC (£GBP) associated with baseline RF changes for HbA1c, body-mass-
index (BMI), systolic blood pressure (SBP), high-density-lipoprotein (HDL) and low-den-
sity-lipoprotein (LDL). A intermediate risk type-2 diabetes cohort (age 52 years, HbA1c 
8%, SBP 140 mm-Hg, BMI 30 Kg/m2, HDL 50 mg/dl and LDL 150 mg/dl) was projected 
over lifetime to explore the sensitivity of undiscounted LYs, QALYs and TLC for selected 
RF ranges (A1c+/-2%, SBP+/-20 mmHg, BMI+/-2 Kg/m2, HDL+/-10 mg/dl, LDL+/-20 mg/
dl). Linear regression models were fitted to assess the degree of end point sensitivity 
per unit RF change. Results: When UK-68-RE were applied, projected changes in 
benefits were 0.264, 0.094, 0.050, -0.611 and 0.162 LYs and 0.288, 0.111, 0.123, -0.358, and 
0.113 QALYs associated with unit RF reductions of 1% point (A1c), 10 mm-HG (SBP), 
1 KG/m2 (BMI), 10 mg/dl (HDL) and 10 mg/dl (LDL), respectively. This compared 
to changes of 0.161, 0.079, 0.053, -0.262, 0.311 (LYs) and 0.215, 0.099,0. 116, -0.178, 
0.208 (QALYs) utilizing UK-82-RE. TLC decreased by £1’105, £298, £115, £680 and £38 
utilizing UK-68-RE and £1’073, £309, -£71, -£221, -£7 with UK-82-RE. cOnclusiOns: 
The degree to which RF changes are translated into benefits and costs may change 
considerably dependent on the choice of selected risk equations.
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dynamic incremental cost-effectiveness ratio (ICER), at the time of market entry 
and by year thereafter. While experts were not aware of any existing guidelines, 
the predominant view was that although using the brand price for the studied drug 
would be a conservative approach, it is reasonable to account for price reductions 
after patent expiration for all drugs considered. cOnclusiOns: Drug price vari-
ations may introduce a source of uncertainty in CEA, as both timing of entry and 
level of generic drug pricing are unknown. There is currently no consensus on how 
this should be considered. Failure to incorporate generic drug entry in CEA is likely 
to yield overestimates of ICER for treatments used over long-term.
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Objectives: Since the results of a cost-effectiveness analysis (CEA) are generally 
sensitive to the input cost parameter values selected for difference disease-related 
outcomes a systematic approach should be used to derive these estimates as sug-
gested in HTA guidance. To determine the extent to which a systematic approach 
was used to select disease-related cost estimates for inclusion in CEAs for new 
hepatitis C treatments. MethOds: A systematic literature review of primary cost-
ing studies and of the cost data used in published CEAs was performed for differ-
ent stages of liver disease for those with chronic hepatitis C infection. The process 
described in the cost-effectiveness analyses by which they selected the input 
base-case cost values as well as the ranges used in the sensitivity analyses was 
reviewed to determine whether or not a systematic approach was used to identify 
primary cost studies and whether or not the a rationale was supplied for the val-
ues selected. Results: The hepatitis C systematic review focused on US costs and 
cost-effectiveness analyses. In most of the hepatitis C cost-effectiveness analyses, 
the cost estimates used were either taken directly or derived from recent primary 
cost studies. However, a systematic review was not generally used to identify the 
recent primary cost studies. In addition, the method used to adapt the data from 
the selected studies for use in the CEA was either not explained and/or appeared to 
be incorrect in some of the CEAs. In most of the CEAs, sensitivity analyses assumed 
arbitrary ranges for the cost estimates (for example, plus or minus 50%) rather than 
using ranges from alternative cost studies. cOnclusiOns: Very little detail is pro-
vided in published CEAs about the methods used to identify primary disease-related 
cost studies and a rationale for selection of the costs is generally not provided.
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Objectives: Current economic evaluations of vaccine immunization strategies 
mainly concentrate on immediate health gains (measured in metrics such as 
QALYs or DALYs) and household cost savings. Vaccine immunization strategies, 
however, often take place within a broader societal context. In order to finan-
cially sustain these strategies, economic evaluations should not only encompass 
immediate health gains and household costs but also the ‘broader value of vac-
cines’. This study aims to identify the relevance of information with regard to 
the broader value of vaccines for decision makers in low and middle income 
countries. MethOds: Several methods were used to identify the broader value 
of vaccines including a literature review, a survey, interviews and consultations 
with experts. The long-term effects of those who were vaccinated and the effects 
experienced by society as a whole, including non-vaccinated community mem-
bers, were included in a framework. Results: In total, twenty broader values 
in five different domains were identified. The first domain included long-term 
productivity gains. These gains refer to the individual long-term productivity due 
to better physical and mental health as well as to the economic consequences of 
decisions made by households due to improved child survival. The second domain 
consists of ecological values which are related to the decline of prevalence and 
incidence of vaccine related diseases. The third domain encompasses different 
types of equity considerations. The fourth domain includes the impact of vaccine 
strategies on other health interventions. Finally, the fifth domain includes macro-
economic effects, such as the impact of vaccine immunization strategies on GDP 
tax revenues and overall government savings. cOnclusiOns: Several broader 
economic values outside the health care sector were identified. These results 
provide the input for the incorporation of these values in economic evaluations. 
Further research is needed to identify the most important broader values for 
national decision makers.
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Objectives: To our knowledge in most articles BIA is only defined as what it does. 
Some authors have tried to define it by comparing it to cost effectiveness analysis. But 
still there is no common stand-alone definition of the term Budget Impact Analysis 
available. Our aim is to provide such a definition. MethOds: In the course of a PhD 
thesis we conducted a systematic literature review in order to identify methodo-
logical articles regarding budget impact analyses. We searched pudmed and seven 
other databases to identify relevant articles. From the eligible articles the different 
understandings and definitions of BIA were extracted and synthesized into a compre-
hensive definition. Results: Our search delivered 223 articles from which 28 met our 
inclusion criteria. 15 different approaches to describe BIAs were identified. Over the 
years (2001 to today) there was a constant improvement and increase of complexity 
in the descriptions. Nevertheless most of the late definitions are based on the work of 
set appears reasonably valid for research, particularly following accreditation. The 
dataset may be a suitable alternative to collecting MR data manually within a trial, 
although caution should be exercised with earlier data. Further work is ongoing to 
establish the nature of the missing data and the implications for cost differences.
PRM27
Can using a ResouRCe use log in an eConoMiC evaluation alongside 
a RandoMised ContRolled tRial ReduCe the aMount of ReCall bias?
Noble S., Tudge I., Wylde V., Lenguerrand E., Marques E.M.
University of Bristol, Bristol, UK
Objectives: To determine whether giving patients a resource use log (RUL) at 
hospital discharge reduces recall bias in a follow-up resource use questionnaire 
(RUQ). MethOds: Within the APEX randomised controlled trials (RCTs), 86 patients 
undergoing joint replacement were randomised to receive or not receive an RUL at 
hospital discharge (The RUL trial). A postal RUQ was then administered to all par-
ticipants at 3-months after surgery. Resource use data (visits to GPs, GP home visits 
and telephone calls; GP practice nurse visits and telephone calls; and prescribed 
medication) in relation to the patient’s joint replacement were extracted from GP 
records from hospital discharge until completion of the 3-month RUQ by a blinded 
researcher. Data from both sources were coded into use of resource and number 
of contacts. For each resource use category, descriptive statistics were calculated 
by data source and RUL trial arm. Kappa statistics and Concordance Correlation 
Coefficients (CCC) were calculated as appropriate. Results: GPs were contacted 
for 67/86 patients originally randomised to receive or not receive an RUL (one had 
surgery delayed, 3 died, 5 withdrew, 6 had GP practices outside of area, 4 did not 
complete the 3-month RUQ). Information was then extracted for 66/67 patients. 
There was evidence of improved recall in favour of the RUL arm in relation to visiting 
a GP (Kappa= 0.5312 vs. -0.0161). There was some slight evidence in favour of the 
non-RUL arm with regards to having a GP home visit (Kappa= 0.335 vs. -0.0937). The 
RUL arm showed more agreement than the non-RUL arm between data sources 
in terms of number of: visits to GPs (CCC= 0.581 vs. -0.013); GP telephone calls 
(CCC= 0.564 vs. 0.173) and prescriptions (CCC= 0.418 vs. -0.13). cOnclusiOns: 
Although based on small numbers, our study found some evidence that provision 
of an RUL reduces recall bias in relation to visits to GPs.
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Objectives: Several new disease modifying therapies have recently received mar-
keting authorisations for the treatment of relapsing-remitting multiple sclerosis 
(RRMS). Given the recent appraisal by NICE of these therapies, the objective of this 
study was to systematically review and critically evaluate the techniques used in 
modelling relapsing-remitting multiple sclerosis in the UK. MethOds: Embase, 
Medline, Cochrane Library and the NICE website were searched systematically on 
03.03.14 to identify articles relating to cost-utility models in RRMS with a UK per-
spective. Data sources, techniques and assumptions of the included models were 
extracted, compared and critically evaluated. Results: Of 385 search results, 25 full 
texts were evaluated and 17 articles (relating to 12 different models) were included. 
Early models varied considerably in method and structure but convergence was 
apparent over time towards a Markov model with states based on disability score, 
a 1-year cycle length and a lifetime time horizon. More recent models also allowed 
for disability improvement within the natural history of the condition. Considerable 
variety remains, however, with an increasing number of comparators over time, the 
need for treatment sequencing and different assumptions around efficacy waning 
and treatment withdrawal. Additionally, modelling techniques were sometimes 
implemented inappropriately. Confidential data sources were frequently used, espe-
cially within the models submitted to NICE. cOnclusiOns: Despite a convergence 
over recent years to a similar Markov structure, there are still significant discrep-
ancies between the models simulating the course of RRMS in the UK. Differing 
methods, assumptions and data sources make the comparison of models, and their 
results, problematic. The Markov structure commonly used also leads to problems 
such as an incapability to deal with heterogeneous populations and multiplying 
complexity with treatment sequences; these would best be solved by using alterna-
tive model types such as discrete event simulations.
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Objectives: Cost-effectiveness analyses (CEA) are used to support funding deci-
sions for new drugs by estimating their clinical and economic value. While prices 
of drugs may fall over time due to market competition, entrance of generic drugs, 
or negotiated price cuts, this is rarely accounted for in CEA. The objective is to 
review pharmacoeconomic guidelines and current practice around drug price evalu-
ation in CEA. MethOds: Pharmacoeconomic guidelines were reviewed to identify 
countries in which a drug price modification over the time horizon is allowed or 
recommended in CEA. Then methodological articles and published CEA using price 
modifications were identified. Finally, several health economics experts were inter-
viewed. Results: Only 3 pharmacoeconomic guidelines report recommendations 
around price adjustment in CEA (Norway, New-Zealand): modellers should take 
into account changes in drug price over time. In France, it is possible to include a 
generic price in sensitivity analysis. In other countries, this was not mentioned in 
the guidelines. Methodological articles mentioned the possibility to use an esti-
mated 4% decrease over time in UK. In most of published CEA incorporating price 
modifications, this was performed as secondary analyses. Other CEA reported 
